1-4 of 4
Antony Chadderton
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Low or Undetectable Levels of Thrombopoietin Receptor (Tpo-R; c-mpl) Expression on Tumor Cell Lines and Primary Tumors Compared with Epo-R, ErbB2, and IGF-1R

Connie L Erickson-Miller, Antony Chadderton, Anna Gibbard, Jennifer Kirchner, Lone Ottesen, Katherine Baker, Lini Pandite, Iman El-Hariry, Yasser Mostafa Kamel, Yuan Liu, Anne-Marie Martin, Conrad Messam
Journal: Blood
Blood (2008) 112 (11): 5394.
https://doi.org/10.1182/blood.V112.11.5394.5394
Published: 2008
Journal Articles

GSK626616: A DYRK3 Inhibitor as a Potential New Therapy for the Treatment of Anemia.

Connie L. Erickson-Miller, PhD, Caretha Creasy, PhD, Antony Chadderton, MS, Christopher B. Hopson, BS, Elizabeth I. Valoret, MS, Michele Gorczyca, MS, Louis Elefante, BA, Don M. Wojchowski, PhD, Matthew Chomo, MS, Duke M. Fitch, PhD, Kevin J. Duffy, PhD
Journal: Blood
Blood (2007) 110 (11): 510.
https://doi.org/10.1182/blood.V110.11.510.510
Published: 2007
Journal Articles

DYRK3 Encodes an Inhibitor of Erythroid Differentiation and Is Expressed at High Levels in Patients with Anemia.

David P. Steensma, MD, Julie C. Porcher, BS, Antony Chadderton, MS, Kevin Laubscher, MS, Deb Jaworski, PhD, Joanne J. Lager, MD, William Bell, MS, JD, Bryan E. Hoffman, PhD, Connie L. Erickson-Miller, PhD
Journal: Blood
Blood (2007) 110 (11): 3661.
https://doi.org/10.1182/blood.V110.11.3661.3661
Published: 2007
Journal Articles

The Characterization of DYRK3 mRNA and the Utility of DYRK3 Inhibitors in a Carboplatin/Radiation Mouse Model of Anemia.

Connie L. Erickson-Miller, PhD, Ying Homan, BA, Matthew Chomo, BS, Elizabeth I. Valoret, MS, Louis Elefante, BA, Amy Landis, MS, Antony Chadderton, MS, Christopher B. Hopson, BA
Journal: Blood
Blood (2007) 110 (11): 2202.
https://doi.org/10.1182/blood.V110.11.2202.2202
Published: 2007